Osteogenic and adipogenic differentiation of rat bone marrow cells on non-mulberry and mulberry silk gland fibroin 3D scaffolds

https://www.utoledo.edu/med/depts/physpharm/pdfs/faculty/abraham/vanella_et_al_bone_2009_kim_ab.pdf

HO-1 expression increases mesenchymal stem cell-derived osteoblasts but decreases adipocyte lineage.

With the increasing worldwide prevalence of diabetes the resulting complications, their consequences and treatment will lead to a greater social and financial burden on society. One of the many organs to be affected is bone. Loss of bone is observed in type 1 diabetes, in extreme cases mirroring osteoporosis, thus a greater risk of fracture. In the case of type 2 diabetes, both a loss and an increase of bone has been observed, although in both cases the quality of the bone overall was poorer, again leading to a greater risk of fracture. Once a fracture has occurred, healing is delayed in diabetes, including nonunion. The reasons leading to such changes in the state of the bone and fracture healing in diabetes is under investigation, including at the cellular and the molecular levels. In comparison with our knowledge of events in normal bone homeostasis and fracture healing, that for diabetes is much more limited, particularly in patients. However, progress is being made, especially with the use of animal models for both diabetes types. Identifying the molecular and cellular changes in the bone in diabetes and understanding how they arise will allow for targeted intervention to improve diabetic bone, thus helping to counter conditions such as Charcot foot as well as preventing fracture and accelerating healing when a fracture does occur.

Review: The diabetic bone: a cellular and molecular perspective.

The use of immobilized osteogenic growth peptide on gradient substrates synthesized via click chemistry to enhance MC3T3-E1 osteoblast proliferation.

Polypeptides with short chains of amino acid monomers have been widely applied in the clinic because of their various biological functions. However, the easily-inactivated characteristics and burst releasing of the peptides limit their application in vivo. Here, a novel osteogenic polypeptide hydrogel (GelMA-c-OGP) is created by co-cross-linking template photo-cross-linked gelatin (GelMA) with photo-cross-linkable osteogenic growth peptides (OGP) using ultraviolet radiation. GelMA enables the formation of hydrogel with photo-cross-linkable OGP with good mechanical properties and also promotes bone regeneration. GelMA-c-OGP hydrogel accelerates the bone formation procedure of osteogenic precursor cells by significantly enhancing the expression of osteogenic-related genes BMP-2, OCN, and OPN, and increasing the precipitation of calcium salts in osteoblasts. Similarly, GelMA-c-OGP hydrogel promotes bone regeneration in vivo. Furthermore, it is observed that more collagen fibers connect cortical bones in the GelMA-c-OGP implanted group than the control group by hematoxylin-eosin and immunohistochemical staining of Collagen I and TGF-β. The co-cross-linked OGP polypeptide converts from liquid to solid hydrogel with transient UV light in situ, which also can strengthen the mechanical property of the defect bone and avoid burst osteogenic peptide, releasing during the bone defect healing period. Overall, this hydrogel delivering system has a significant impact on bone defect healing compared with traditional methods.

Gelatin Templated Polypeptide Co-Cross-Linked Hydrogel for Bone Regeneration.

Osteogenic growth peptide C-terminal pentapeptide [OGP(10-14)] acts on rat bone marrow mesenchymal stem cells to promote differentiation to osteoblasts and to inhibit differentiation to adipocytes.

In neonatal rat metatarsal organ culture, a bell-shaped dose-related curve in length of mineralized area, increases in the height of proliferative and hypertrophic zones, in the number of hypertrophic chondrocyte and in the amount of Runx2 mRNA, were revealed after treatment with OGP(10-14). We conclude that OGP(10-14) accelerates bone growth.

Li Zhao

Papers

Osteogenic growth peptide C-terminal pentapeptide [OGP(10-14)] acts on rat bone marrow mesenchymal stem cells to promote differentiation to osteoblasts and to inhibit differentiation to adipocytes.

Regulation of Endochondral Ossification by Osteogenic Growth Peptide CTerminal Pentapeptide [OGP(10-14)]